<DOC>
	<DOCNO>NCT02034968</DOCNO>
	<brief_summary>There report suggest anti-epidermal growth factor antibody nimotuzumab advantageous advanced esophageal cancer patient combination chemotherapy radiotherapy.And , albumin-bound paclitaxel characterize high tolerate dos great efficacy , great concentration tumor tissue compare normal tissues.So , The objective single-arm phase II trial evaluate benefit nimotuzumab plus nab-paclitaxel cisplatin patient advance esophageal carcinoma .</brief_summary>
	<brief_title>Nimotuzumab Plus Nab-paclitaxel Cisplatin Treating Patients With Advanced Esophageal Carcinoma</brief_title>
	<detailed_description>In past decade , clinical trial evaluate role chemotherapy , radiation , , patient advance esophageal carcinoma , fail demonstrate consistent survival benefit . In Eastern country , Chemotherapy become one treatment strategy advance esophageal cancer . In effort improve efficacy systemic chemotherapy , investigator conduct prospective study evaluate regimen Nimotuzumab plus Nab-paclitaxel/cisplatin patient advanced esophageal squamous cell carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patient confirm stage IV esophageal carcinoma pathologic histology cytology . Males female age ≥18 year , &lt; 75 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Life expectancy ≥12 week . Adequate bone marrow , renal , liver function require . Able comply require protocol followup procedure , able receive oral medication . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . Allergy antiEGFR antibody . Female subject pregnant breastfeeding . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L , Platelet count ≥100 x 109/L . Adequate renal function : Serum creatinine ≤ 1.5 x ULN , ≥ 50 ml/min . Adequate liver function : total bilirubin &lt; 1.5 x upper limit normal ( ULN ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastasis . Patient assess investigator unable unwilling comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Nimotuzumab</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Carcinoma Esophagus</keyword>
</DOC>